BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35380342)

  • 1. CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.
    Chen J; Jiang S; Shao H; Li B; Ji T; Staiculescu D; He J; Zhao J; Cai L; Liang X; Xu J; Cai X
    Sci China Life Sci; 2022 Oct; 65(10):1998-2016. PubMed ID: 35380342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
    Elkateb AS; Nofal S; Ali SA; Atya HB
    Inflammation; 2023 Aug; 46(4):1493-1511. PubMed ID: 37171695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
    Yang C; Lu T; Liu M; Yuan X; Li D; Zhang J; Zhou L; Xu M
    Phytomedicine; 2023 Mar; 111():154668. PubMed ID: 36657316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC.
    Gao Q; Zhang G; Zheng Y; Yang Y; Chen C; Xia J; Liang L; Lei C; Hu Y; Cai X; Zhang W; Tang H; Chen Y; Huang A; Wang K; Tang N
    Cell Death Differ; 2020 Mar; 27(3):1086-1104. PubMed ID: 31367013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis.
    Zhang Y; Tan Y; Liu S; Yin H; Duan J; Fan L; Zhao X; Jiang B
    Toxicol Mech Methods; 2023 Jan; 33(1):47-55. PubMed ID: 35592903
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Lu J; Ding Y; Zhang W; Qi Y; Zhou J; Xu N; Zhang Y; Xie W
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of the protein-protein interaction between phosphorylated p62 and Keap1 attenuate chemoresistance in a human hepatocellular carcinoma cell line.
    Yasuda D; Ohe T; Takahashi K; Imamura R; Kojima H; Okabe T; Ichimura Y; Komatsu M; Yamamoto M; Nagano T; Mashino T
    Free Radic Res; 2020 Dec; 54(11-12):859-871. PubMed ID: 32075457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway.
    Li J; Wang Q; Yang Y; Lei C; Yang F; Liang L; Chen C; Xia J; Wang K; Tang N
    J Exp Clin Cancer Res; 2019 Oct; 38(1):438. PubMed ID: 31666108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation and role of nuclear factor-E2-related factor 2 (Nrf2) in multidrug resistance of hepatocellular carcinoma.
    Tian B; Lu ZN; Guo XL
    Chem Biol Interact; 2018 Jan; 280():70-76. PubMed ID: 29223570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma.
    Wang Z; Pan B; Yao Y; Qiu J; Zhang X; Wu X; Tang N
    Biomed Pharmacother; 2023 Apr; 160():114402. PubMed ID: 36791564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
    Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
    J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines.
    Haque E; Śmiech M; Łuczyńska K; Bouchard MF; Viger R; Kono H; Pierzchała M; Taniguchi H
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nrf2 Mutation/Activation Is Dispensable for the Development of Chemically Induced Mouse HCC.
    Mattu S; Zavattari P; Kowalik MA; Serra M; Sulas P; Pal R; Puliga E; Sutti S; Foglia B; Parola M; Albano E; Giordano S; Perra A; Columbano A
    Cell Mol Gastroenterol Hepatol; 2022; 13(1):113-127. PubMed ID: 34530178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing
    Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
    Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of phosphorylated p62 is associated with NF-E2-related factor 2 activation in hepatocellular carcinoma.
    Shimizu T; Inoue K; Hachiya H; Shibuya N; Aoki T; Kubota K
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):467-71. PubMed ID: 27246794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil.
    Shi L; Wu L; Chen Z; Yang J; Chen X; Yu F; Zheng F; Lin X
    Cell Physiol Biochem; 2015; 35(6):2333-48. PubMed ID: 25896253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC.
    Chan YT; Wu J; Lu Y; Li Q; Feng Z; Xu L; Yuan H; Xing T; Zhang C; Tan HY; Feng Y; Wang N
    Mol Cancer; 2024 Apr; 23(1):74. PubMed ID: 38582885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative subcellular localization of NRF2 and KEAP1 during the hepatocellular carcinoma development in vivo.
    Guerrero-Escalera D; Alarcón-Sánchez BR; Arellanes-Robledo J; Cruz-Rangel A; Del Pozo-Yauner L; Chagoya de Sánchez V; Resendis-Antonio O; Villa-Treviño S; Torres-Mena JE; Pérez-Carreón JI
    Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119222. PubMed ID: 35093454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.
    Lu Z; Yang H; Shao Y; Sun W; Jiang Y; Li J
    Biochem Biophys Res Commun; 2022 Oct; 627():103-110. PubMed ID: 36030651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UBR7 inhibits HCC tumorigenesis by targeting Keap1/Nrf2/Bach1/HK2 and glycolysis.
    Zhao L; Kang M; Liu X; Wang Z; Wang Y; Chen H; Liu W; Liu S; Li B; Li C; Chang A; Tang B
    J Exp Clin Cancer Res; 2022 Nov; 41(1):330. PubMed ID: 36419136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.